Understanding HMP Global Market Access Insights' New Payer Report Series

Article

Understanding HMP Global Market Access Insights' New Payer Report Series

March 10, 2022
Authors
Topics

Welcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.

Reading a tablet

Greetings From San Mateo!

Welcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.

Why Payers? The insurance marketplace has become increasingly consolidated, and companies are looking for new avenues for growth. Large, horizontal mergers reached a standstill when the Cigna + Anthem merger was blocked by a U.S. district court resulting in a termination of the agreement. Payers are now focusing on vertical integration, and blurring the lines between insurer, PBM, SP, and Provider.

Payers are, in some cases, now acting as "virtual IDNs" enabling them to manage the initial referral and capture downstream revenues (see below).

 

Grappling With the (Payer) Octopus 

We see several trends continuing to accelerate in this "Vertical Era": 

1. Payers and Providers will increasingly compete to control patients. Expect provider consolidation as competition weeds out the weak. Monitor payer expansion from "easy" opportunities such as senior care into high-cost and high-complexity areas including oncology. 

2. "Virtual First" plans become commonplace. Payers save money by asking patients to initiate care using a phone or video encounter. Patients are then directed to the insurers' preferred providers for subsequent care, subject to strict prescribing controls. These narrow specialty networks increase plans' influence on treatment selection.

3. Manufacturers will need to track their relationships and financial arrangements across an entire vertical payer organization. Vertical payers will inevitably have internal conflicts as priorities among subsidiaries vary, most likely between an insurer’s search for low total cost of care and a PBM’s search for rebates, admin, and data fees. Manufacturers should assess each vertical payer’s level of integration and adapt their commercial interactions to optimize their results across the entire payer vertical.

If you like what you see, stay tuned! We are planning to release a payer podcast this April. As always, please reach out with any questions or comments you may have.

All the best...
-- HMP Market Access Insights Team

The Latest

Meet Ashutosh Sheth
Article
Meet Ashu: Organizer & Researcher Extraordinaire; Artist at Heart

Ashu is the glue that keeps our team organized and running smoothly. This year, he’s been particularly fascinated by the growing consolidation among community practices and how it’s reshaping the oncology landscape.

Ashutosh Sheth
Beyond AMCs: CAR Ts and Bispecifics in Community Oncology
Article
Beyond AMCs: CAR Ts and Bispecifics in Community Oncology

CAR T-cell and BsAb therapies are powerful but largely confined to AMCs, limiting patient access. Our latest report explores how expanding to community oncology could improve access, addressing key clinical, logistical, and financial challenges.

Chris Van Denburg
Not only does Emma have over a decade of experience supporting academic health systems and integrated delivery networks (IDNs), but she’s also the go-to for a delicious apple pie.
Article
Meet Emma: Research Leader and Master Baker

Not only does Emma have over a decade of experience supporting academic health systems and integrated delivery networks (IDNs), but she’s also the go-to for a delicious apple pie.

Emma Bijesse